DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 4 filers reported holding DENALI THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $949,021 | -28.5% | 46,002 | +2.3% | 0.00% | -20.0% |
Q2 2023 | $1,326,652 | +211.1% | 44,956 | +142.9% | 0.01% | +150.0% |
Q1 2023 | $426,401 | -26.6% | 18,507 | -11.5% | 0.00% | -33.3% |
Q4 2022 | $581,285 | -55.7% | 20,902 | -51.1% | 0.00% | -57.1% |
Q3 2022 | $1,312,000 | +1.5% | 42,741 | -2.7% | 0.01% | +16.7% |
Q2 2022 | $1,293,000 | -4.9% | 43,919 | +3.9% | 0.01% | +20.0% |
Q1 2022 | $1,359,000 | -25.9% | 42,252 | +2.8% | 0.01% | -28.6% |
Q4 2021 | $1,833,000 | -12.5% | 41,092 | -1.0% | 0.01% | -30.0% |
Q3 2021 | $2,095,000 | -20.1% | 41,522 | +24.2% | 0.01% | -16.7% |
Q2 2021 | $2,622,000 | +170.6% | 33,432 | +96.9% | 0.01% | +200.0% |
Q1 2021 | $969,000 | -45.1% | 16,975 | -19.5% | 0.00% | -50.0% |
Q4 2020 | $1,765,000 | +444.8% | 21,076 | +132.9% | 0.01% | +700.0% |
Q3 2020 | $324,000 | -15.6% | 9,051 | -43.0% | 0.00% | -50.0% |
Q2 2020 | $384,000 | +9.4% | 15,880 | -20.8% | 0.00% | 0.0% |
Q1 2020 | $351,000 | – | 20,050 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Crestline Management, LP | 5,960,732 | $122,969,901 | 14.32% |
ARCH Venture Management, LLC | 693,749 | $14,312,042 | 9.30% |
Flagship Pioneering Inc. | 2,619,968 | $54,049,940 | 3.92% |
Casdin Capital, LLC | 1,300,000 | $26,819,000 | 2.97% |
Yiheng Capital Management, L.P. | 1,150,684 | $23,738,611 | 1.21% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 154,000 | $3,172,400 | 1.07% |
SECTORAL ASSET MANAGEMENT INC | 254,941 | $5,259,433 | 1.02% |
Temasek Holdings (Private) Ltd | 6,895,992 | $142,264,315 | 0.85% |
Clarius Group, LLC | 378,262 | $7,803,545 | 0.74% |
Artal Group S.A. | 802,899 | $16,564 | 0.71% |